Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
1. 5.1: Introduction - p. 74 2. 5.2: Methods for evaluating antiviral activities of natural bioactive molecules against SARS coronaviruses - p. 75 3. 5.3: Treatment of SARS coronavirus infections with natural products from plants origin - p. 77 4. 5.4: Isolated molecules from plants for treatment of SARS coronavirus infections - p. 97 5. 5.5: Treatment of SARS coronavirus infections by microbial, animal, and human bioactive molecules - p. 123 6. 5.6: In vivo and clinical studies of natural medicines for the treatment of SARS coronavirus infections - p. 127 7. 5.7: Evaluation of in silico antiviral activity of natural medicines for the treatment of COVID-19 infections - p. 129 8. 5.8: Relationship between of SARS-CoV and COVID-19 treatment using natural drugs - p. 144 9. 5.9: Conclusion and perspectives - p. 144 10. Chapter 6 Plants with potent antiviral properties - p. 155 11. Chapter 7 Herbal-based resources against exanthematous viral infections and other viral diseases - p. 173 12. Chapter 8 Dietary polyphenols as therapeutic agents to combat COVID-19 - p. 203 13. Chapter 9 Computational demonstration of cheminformatics and machine learning in coronavirus drug discovery - p. 219 14. Chapter 10 In silico approaches in drug discovery for SARS-CoV-2 - p. 235 15. Chapter 11 Application of molecular docking and dynamics tools in SARS-CoV-2 drug design - p. 253 16. Chapter 12 Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 - p. 273 17. Chapter 13 Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 - p. 299 18. Chapter 14 In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins - p. 313 19. Chapter 15 In silico evaluation of anti-SARS-CoV-2 activity of Punica granatum L. phytochemicals - p. 335 20. Chapter 16 In silico investigation and identification of bioactive compounds from medicinal plants as potential inhibitors against SARS-CoV-2 cellular entry - p. 355 21. Index - p. 377
Coronavirus Drug Discovery, Volume Three: Druggable Targets and In Silico Update presents comprehensive information on drug discovery against COVID-19. Chapters in Part One of this volume describe the various druggable targets and associated signaling pathways for effective targeting of SARS-CoV-2. In Part Two, chapters discuss the various computational approaches and in silico studies against SARS-CoV-2. Written by global team of experts, this book is an excellent resource that will be extremely useful to drug developers, medicinal chemists, pharmaceutical companies in R&D, research institutes in both academia and industry, and the National Library of Medicines and Health.
In addition, agencies such as the National Institutes of Health, Centers for Disease Control and Prevention, World Health Organization, European Medicines Agency, the US Food and Drug Administration, and all others involved in drug discovery against COVID-19 will find this book useful.
1. 5.1: Introduction - p. 74 2. 5.2: Methods for evaluating antiviral activities of natural bioactive molecules against SARS coronaviruses - p. 75 3. 5.3: Treatment of SARS coronavirus infections with natural products from plants origin - p. 77 4. 5.4: Isolated molecules from plants for treatment of SARS coronavirus infections - p. 97 5. 5.5: Treatment of SARS coronavirus infections by microbial, animal, and human bioactive molecules - p. 123 6. 5.6: In vivo and clinical studies of natural medicines for the treatment of SARS coronavirus infections - p. 127 7. 5.7: Evaluation of in silico antiviral activity of natural medicines for the treatment of COVID-19 infections - p. 129 8. 5.8: Relationship between of SARS-CoV and COVID-19 treatment using natural drugs - p. 144 9. 5.9: Conclusion and perspectives - p. 144 10. Chapter 6 Plants with potent antiviral properties - p. 155 11. Chapter 7 Herbal-based resources against exanthematous viral infections and other viral diseases - p. 173 12. Chapter 8 Dietary polyphenols as therapeutic agents to combat COVID-19 - p. 203 13. Chapter 9 Computational demonstration of cheminformatics and machine learning in coronavirus drug discovery - p. 219 14. Chapter 10 In silico approaches in drug discovery for SARS-CoV-2 - p. 235 15. Chapter 11 Application of molecular docking and dynamics tools in SARS-CoV-2 drug design - p. 253 16. Chapter 12 Molecular dynamic simulation with protein and detection of repurposable drugs for COVID-19 - p. 273 17. Chapter 13 Computation-guided inhibitor screening against the nucelocapsid of SARS-CoV-2 - p. 299 18. Chapter 14 In silico insight into the interaction of 4-aminoquinolines with selected SARS-CoV-2 structural and nonstructural proteins - p. 313 19. Chapter 15 In silico evaluation of anti-SARS-CoV-2 activity of Punica granatum L. phytochemicals - p. 335 20. Chapter 16 In silico investigation and identification of bioactive compounds from medicinal plants as potential inhibitors against SARS-CoV-2 cellular entry - p. 355 21. Index - p. 377
